Claims
- 1. A method for treating hyperproliferative disease, said method comprising administering to a patient in need of such treatment a combination of one or more epothilones and one or more nucleoside analogs.
- 2. The method of claim 1 wherein administration of one or more epothilones and administration of one or more nucleoside analogs are simultaneous.
- 3. The method of claim 2 wherein the epothilone is selected from the group consisting of epothilone B, epothilone D, 21-hydroxyepothilone B, 21-hydroxyepothilone D, 21-aminoepothilone B, 21-aminoepothilone D, azaepothilone B, azaepothilone D, 9,10-dehydroepothilone B, 9,10-dehydroepothilone D, 26-trifluoro-9,10-dehydroepothilone B, and 26-trifluoro-9,10-dehydroepothilone D.
- 4. The method of claim 2 wherein the nucleoside analog is selected from the group consisting of azacitidine, cladribine, cytarabine, floxuridine, fludarabine phosphate, 5-fluorouracil, gemcitabine, pentostatin, uracil mustard, and 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine.
- 5. The method of claim 2 wherein the epothilone is epothilone D and the nucleoside analog is selected from the group consisting of 5-fluorouracil and 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine.
- 6. The method of claim 2 wherein administration of the epothilone results in a dosage of between about 1 mg/m2 and about 200 mg/m2.
- 7. The method of claim 1 wherein administration of one or more epothilone occurs first, followed by administration of one or more nucleoside analog.
- 8. The method of claim 7 wherein the epothilone is selected from the group consisting of epothilone B, epothilone D, 21-hydroxyepothilone B, 21-hydroxyepothilone D, 21-aminoepothilone B, 21-aminoepothilone D, azaepothilone B, azaepothilone D, 9,10-dehydroepothilone B, 9,10-dehydroepothilone D, 26-trifluoro-9,10-dehydroepothilone B, and 26-trifluoro-9,10-dehydroepothilone D.
- 9. The method of claim 7 wherein the nucleoside analog is selected from the group consisting of azacitidine, cladribine, cytarabine, floxuridine, fludarabine phosphate, 5-fluorouracil, gemcitabine, pentostatin, uracil mustard, and 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine.
- 10. The method of claim 7 wherein the epothilone is epothilone D and the nucleoside analog is selected from the group consisting of 5-fluorouracil and 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine.
- 11. The method of claim 7 wherein administration of the epothilone results in a dosage of between about 1 mg/m2 and about 200 mg/m2.
- 12. The method of claim 1 wherein administration of one or more nucleoside analog occurs first, followed by administration of one or more epothilone.
- 13. The method of claim 12 wherein the epothilone is selected from the group consisting of epothilone B, epothilone D, 21-hydroxyepothilone B, 21-hydroxyepothilone D, 21-aminoepothilone B, 21-aminoepothilone D, azaepothilone B, azaepothilone D, 9,10-dehydroepothilone B, 9,10-dehydroepothilone D, 26-trifluoro-9,10-dehydroepothilone B, and 26-trifluoro-9,10-dehydroepothilone D.
- 14. The method of claim 12 wherein the nucleoside analog is selected from the group consisting of azacitidine, cladribine, cytarabine, floxuridine, fludarabine phosphate, 5-fluorouracil, gemcitabine, pentostatin, uracil mustard, and 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine.
- 15. The method of claim 12 wherein the epothilone is epothilone D and the nucleoside analog is selected from the group consisting of 5-fluorouracil and 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine.
- 16. The method of claim 12 wherein administration of the epothilone results in a dosage of between about 1 mg/m2 and about 200 mg/m2.
- 17. The method of claim 12 wherein administration of the epothilone results in a dosage of between about 1 mg/m2 and about 200 mg/m2.
- 18. The method of claim 1 wherein said hyperproliferative disease is cancer.
- 19. The method of claim 18 wherein the cancer is selected from the group consisting of colorectal cancer, breast cancer, and non-small cell lung cancer.
- 20. The method of claim 19 wherein the cancer is colorectal cancer or breast cancer.
- 21. A combination of one or more epothilones and one or more nucleoside analogs for separate, simultaneous or sequential use in the treatment of a hyperproliferative disease.
- 22. The combination of claim 21, wherein the epothilone is selected from the group consisting of epothilone B, epothilone D, 21-hydroxyepothilone B, 21-hydroxyepothilone D, 21-aminoepothilone B, 21-aminoepothilone D, azaepothilone B, azaepothilone D, 9,10-dehydroepothilone B, 9,10-dehydroepothilone D, 26-trifluoro-9,10-dehydroepothilone B, and 26-trifluoro-9,10-dehydroepothilone D.
- 23. The combination of claim 21, wherein the nucleoside analog is selected from the group consisting of azacitidine, cladribine, cytarabine, floxuridine, fludarabine phosphate, 5-fluorouracil, gemcitabine, pentostatin, uracil mustard, and 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine.
- 24. The combination of claim 21, wherein the epothilone is epothilone D and the nucleoside analog is selected from the group consisting of 5-fluorouracil and 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine.
- 25. The combination of claim 21, wherein the hyperproliferative disease is cancer.
- 26. The combination of claim 25, wherein the cancer is selected from the group consisting of colorectal cancer, breast cancer, and non-small cell lung cancer.
- 27. The combination of claim 21, wherein the treatment involves administering the one or more epothilones and the one or more nucleoside analogs simultaneously.
- 28. The combination of claim 21, wherein the treatment involves administering the one or more epothilones first, followed by the one or more nucleoside analogs.
- 29. The combination of claim 21, wherein the treatment results in a dosage of the one or more epothilones of between about 1 mg/m2 and about 200 mg/m2.
- 30. Use of one or more epothilones and one or more nucleoside analogs for the manufacture of a medicament for use in conjunction for the treatment of a hyperproliferative disease.
- 31. The use of claim 30, wherein the epothilone is selected from the group consisting of epothilone B, epothilone D, 21-hydroxyepothilone B, 21-hydroxyepothilone D, 21-aminoepothilone B, 21-aminoepothilone D, azaepothilone B, azaepothilone D, 9,10-dehydroepothilone B, 9,10-dehydroepothilone D, 26-trifluoro-9,10-dehydroepothilone B, and 26-trifluoro-9,10-dehydroepothilone D.
- 32. The use of claim 30, wherein the nucleoside analog is selected from the group consisting of azacitidine, cladribine, cytarabine, floxuridine, fludarabine phosphate, 5-fluorouracil, gemcitabine, pentostatin, uracil mustard, and 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine.
- 33. The use of claim 30, wherein the epothilone is epothilone D and the nucleoside analog is selected from the group consisting of 5-fluorouracil and 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine.
- 34. The use of claim 30, wherein the hyperproliferative disease is cancer.
- 35. The use of claim 34, wherein the cancer is selected from the group consisting of colorectal cancer, breast cancer, and non-small cell lung cancer.
- 36. The use of claim 30, wherein the treatment involves administering the one or more epothilones and the one or more nucleoside analogs simultaneously.
- 37. The use of claim 30, wherein the treatment involves administering the one or more epothilones first, followed by the one or more nucleoside analogs.
- 38. The use of claim 30, wherein the treatment results in a dosage of the one or more epothilones of between about 1 mg/m2 and about 200 mg/m2.
- 39. Use of one or more epothilones for the manufacture of a medicament for administration in conjunction with one or more nucleoside analogs for the treatment of a hyperproliferative disease.
- 40. The use of claim 39, wherein the epothilone is selected from the group consisting of epothilone B, epothilone D, 21-hydroxyepothilone B, 21-hydroxyepothilone D, 21-aminoepothilone B, 21-aminoepothilone D, azaepothilone B, azaepothilone D, 9,10-dehydroepothilone B, 9,10-dehydroepothilone D, 26-trifluoro-9,10-dehydroepothilone B, and 26-trifluoro-9,10-dehydroepothilone D.
- 41. The use of claim 39, wherein the nucleoside analog is selected from the group consisting of azacitidine, cladribine, cytarabine, floxuridine, fludarabine phosphate, 5-fluorouracil, gemcitabine, pentostatin, uracil mustard, and 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine.
- 42. The use of claim 39, wherein the epothilone is epothilone D and the nucleoside analog is selected from the group consisting of 5-fluorouracil and 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine.
- 43. The use of claim 39, wherein the hyperproliferative disease is cancer.
- 44. The use of claim 43, wherein the cancer is selected from the group consisting of colorectal cancer, breast cancer, and non-small cell lung cancer.
- 45. The use of claim 39, wherein the treatment involves administering the one or more epothilones and the one or more nucleoside analogs simultaneously.
- 46. The use of claim 39, wherein the treatment involves administering the one or more epothilones first, followed by the one or more nucleoside analogs.
- 47. The use of claim 39, wherein the treatment results in a dosage of the one or more epothilones of between about 1 mg/m2 and about 200 mg/m2.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority under 35 U.S.C. 119(e) to U.S. Provisional Application Serial No. 60/417,535, filed 9 Oct. 2002, the contents of which are incorporated herein by reference in their entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60417535 |
Oct 2002 |
US |